Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis

Cancer Letters

Volumn 276, Issue 2, 2009, Pages 228-238

  Coss, Alan ^a   Tosetto, Miriam ^b   Fox, Edward J ^b   Sapetto Rebow, Beata ^b   Gorman, Sheeona ^a   Kennedy, Breandán N ^b   Lloyd, Andrew T ^c   Hyland, John M ^a   O'Donoghue, Diarmuid P ^a   Sheahan, Kieran ^a   Leahy, Dermot T ^b   Mulcahy, Hugh E ^a   O'Sullivan, Jacintha N ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Array CGH; Cell cycle; Chemotherapy; Colon cancer; Colorectal cancer; Disease progression; Drug resistance; Gene amplification; HER2; Oncology; Topisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; CHROMOSOMAL INSTABILITY; COLORECTAL TUMOR; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; APOPTOSIS; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 60849131861     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.018     Document Type: Article

References (43)

1. Bofin A.M., Ytterhus B., and Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14 (2003) 314-319
2. Hansel D.E., Ashfaq R., Rahman A., et al. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIb alpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment. Am. J. Clin. Pathol. 123 (2005) 28-35
3. Jarvinen T.A., Tanner M., Barlund M., Borg A., and Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26 (1999) 142-150
4. Kanta S.Y., Yamane T., Dobashi Y., Mitsui F., Kono K., and Ooi A. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum. Pathol. 37 (2006) 1333-1343
5. Kruger S., Lange I., Kausch I., and Feller A.C. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder-a multitissue array study with prognostic implications. Anticancer Res. 25 (2005) 263-271
6. Rudolph P., Kellner U., Chassevent A., et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study. Am. J. Pathol. 150 (1997) 1997-2007
7. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish breast cancer cooperative group. J. Clin. Oncol. 23 (2005) 7483-7490
8. Rudolph P., MacGrogan G., Bonichon F., et al. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Br. Cancer Res. Treat. 55 (1999) 61-71
9. Al-Kuraya K., Novotny H., Bavi P., et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J. Clin. Pathol. 60 (2007) 768-772
10. Staley B.E., Samowitz W.S., Bronstein I.B., and Holden J.A. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Model. Pathol. 12 (1999) 356-361
11. Zorzos H.S., Lazaris A.C., Korkolopoulou P.A., et al. Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential. Pathology 35 (2003) 315-318
12. Turley H., Comley M., Houlbrook S., et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer 75 (1997) 1340-1346
13. Huang L., Shitashige M., Satow R., et al. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Gastroenterology 133 (2007) 1569-1578
14. AJCC (American Joint Committee on Cancer). Cancer Staging Manual. 6th ed. (2002), Springer, New York
15. Culhane A.C., Perriere G., Considine E.C., Cotter T.G., and Higgins D.G. Between-group analysis of microarray data. Bioinformatics 18 (2002) 1600-1608
16. Thioulouse J.C.D., Doledec S., and Olivier J.M. ADE-4: a multivariate analysis and graphical display software. Stat. Comput. 7 (1997) 75-83
17. Fox E.J., Leahy D.T., Geraghty R., et al. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J. Mol. Diagnosis. 8 (2006) 68-75
18. Nakao K., Mehta K.R., Fridlyand J., et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 25 (2004) 1345-1357
19. Douglas E.J., Fiegler H., Rowan A., et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res. 64 (2004) 4817-4825
20. Camps J., Armengol G., del Rey J., et al. Genome-wide differences between microsatellite stable and unstable colorectal tumors. Carcinogenesis 27 (2006) 419-428
21. Davison E.J., Tarpey P.S., Fiegler H., Tomlinson I.P., and Carter N.P. Deletion at chromosome band 20p121 in colorectal cancer revealed by high resolution array comparative genomic hybridization. Genes Chromosomes Cancer 44 (2005) 384-391
22. Gaasenbeek M., Howarth K., Rowan A.J., et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res. 66 (2006) 3471-3479
23. Jones A.M., Douglas E.J., Halford S.E., et al. Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 24 (2005) 118-129
24. Tsafrir D., Bacolod M., Selvanayagam Z., et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res. 66 (2006) 2129-2137
25. Jarvinen T.A., Holli K., Kuukasjarvi T., and Isola J.J. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer. 77 (1998) 2267-2273
26. Durbecq V., Di Leo A., Cardoso F., et al. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Br. Cancer Res. Treat. 77 (2003) 199-204
27. Varis A., Wolf M., Monni O., et al. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res. 62 (2002) 2625-2629
28. Tsiambas E., Karameris A., Tiniakos D.G., and Karakitsos P. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. Pancreatology 7 (2007) 45-52
29. Lazaris A.C., Kavantzas N.G., Zorzos H.S., Tsavaris N.V., and Davaris P.S. Markers of drug resistance in relapsing colon cancer. J. Cancer Res. Clin. Oncol. 128 (2002) 114-118
30. Shapiro P.S., Whalen A.M., Tolwinski N.S., et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol. Cell. Biol. 19 (1999) 3551-3560
31. Arnaout A.H., Dawson P.M., Soomro S., et al. HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J. Clin. Pathol. 45 (1992) 726-727
32. Ochs A.M., Wong L., Kakani V., et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin. Colorectal. Cancer 4 (2004) 262-267
33. Kay E.W., Mulcahy H., Walsh C.B., Leader M., and O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 25 (1994) 455-461
34. Li J.W., Chuang T.C., Yang A.H., Hsu C.K., and Kao M.C. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan. Int. J. Oncol. 26 (2005) 933-943
35. Osako T., Miyahara M., Uchino S., Inomata M., Kitano S., and Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55 (1998) 548-555
36. Kellner U., Sehested M., Jensen P.B., Gieseler F., and Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 3 (2002) 235-243
37. Fry A.M., Chresta C.M., Davies S.M., et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51 (1991) 6592-6595
38. Houlbrook S., Addison C.M., Davies S.L., et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer. 72 (1995) 1454-1461
39. Di Leo A., Gancberg D., Larsimont D., et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 8 (2002) 1107-1116
40. Bartlett J.M., Munro A., Cameron D.A., Thomas J., Prescott R., and Twelves C.J. Type 1 receptor tyrosine Kkinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J. Clin. Oncol. (2008)
41. Henness S., Davey M.W., Harvie R.M., and Davey R.A. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 895-902
42. Pang E., Hu Y., Chan K.Y., et al. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Lab. Invest. 85 (2005) 664-674
43. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer. Res. 58 (1998) 5315-5320